Menu visibility control

Video

Events

Startup Surgery

Most Recent

Need to Know

Here’s how your tech firm can exploit the podcasting revolution

Investments

Cheshire-based mobile app SurveyMy gets £2m

The Week in Tech

A £12m series B, a £57.5m fund for Northern SMEs, a hoverbike and more in The Week in Tech

Press Releases

Software testing leader TestPlant appoints Dr. John Bates as CEO
CreditLadder appoints Proptech Expert Sheraz Dar as new CEO
Hermit: A Startup With New Ideas About Office Space

Life science firms turning to crowdfunding for finance

Life Science
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

European life sciences companies are increasingly using equity crowdfunding to finance their growth, a new report from market analyst BIOCOM AG has revealed.

The report titled “Analysis of Crowd-based Financing in European Life Sciences” found that UK equity crowdfunding platform SyndicateRoom leads the way when it comes to life science fundraising.

Since its launch two years ago SyndicateRoom has completed 16 life science raises across Europe.

Crowdfunding: what it is and how it works

The found that since 2010, crowdfunding platforms have raised £17m across Europe for 42 life science businesses, with an average raise of around £400K.

Most of this momentum has been in recent years, with nine raises in 2013, 18 raises in 2014 and 13 in the first half of 2015.

SyndicateRoom alone accounts for almost 40% of those raises.

Report author Sandra Wirsching said: “With respect to the high capital demand in the life sciences, it was only a question of time before firms jumped on the bandwagon of crowd financing.

“It is considered as a marketing tool and add-on to other financing instruments.”

“British crowdfunding platforms are amongst the most experienced in Europe. This is mostly due to Britain’s favourable regulatory framework that supports investment in higher-risk technology companies. Furthermore, platforms with strong ties to professional investors, such as SyndicateRoom, fit best to the high capital demand of life science companies.”

SyndicateRoom CEO Gonçalo de Vasconcelos added: “Our unique investor-led model allows our members to co-invest alongside experienced angel investors in highly sophisticated investment opportunities on the same economic terms as the lead investors.

“This is a powerful and successful model for life sciences businesses as they raise capital, as well as a range of other industries, including pharmaceuticals, information technology, property and even movie making.

“We’re particularly proud to lead Europe in life sciences, against a field that includes specialist life sciences platforms. This is a testament to the strength of our model, uniting the crowd with professional investors that often have deep, sector-specific expertise.”

The full BIOCOM report is available here.

 

Enter your e-mail address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

podcasting revolution

Here’s how your tech firm can exploit the podcasting revolution
posted 1 hour ago

Lee Evans - SurveyMe

Cheshire-based mobile app SurveyMy gets £2m
posted 2 hours ago

TWIT - Emily 23.02.17

A £12m series B, a £57.5m fund for Northern SMEs, a hoverbike and more in The Week in Tech
posted 5 hours ago

Team_Monzo

Challenger bank Monzo announces £19.5m investment
posted 24 hours ago

hostmaker

Hostmaker raises £5m Series A from French VC firm Ventech
posted on February 23, 2017

caspar

EXCLUSIVE: AR startup Zappar lands $3.75m Series A
posted on February 23, 2017